Provided by Tiger Trade Technology Pte. Ltd.

Insmed

122.58
+2.662.22%
Pre-market: 123.951.37+1.12%04:41 EDT
Volume:1.43M
Turnover:175.68M
Market Cap:26.77B
PE:-29.98
High:124.41
Open:120.00
Low:119.55
Close:119.92
52wk High:212.75
52wk Low:90.39
Shares:218.38M
Float Shares:216.82M
Volume Ratio:0.59
T/O Rate:0.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.0882
EPS(LYR):-6.4200
ROE:-87.22%
ROA:-22.17%
PB:35.34
PE(LYR):-19.09

Loading ...

Guggenheim Reaffirms Their Buy Rating on Insmed (INSM)

TIPRANKS
·
Jul 22

Ritu Baral Reaffirms Buy on Insmed, Raising Price Target from $200 to $243 Ahead of Q2 Preview

TIPRANKS
·
Jul 22

Insmed initiated with an Outperform at BMO Capital

TIPRANKS
·
Jul 21

Is Insmed (INSM) Undervalued After Positive TPIP Data Backed A Phase 3 Push?

Simply Wall St.
·
Jul 20

Insmed (INSM) Reports 12 Month TPIP Data That Sets Up Phase 3

Simply Wall St.
·
Jul 19

Analysts’ Top Healthcare Picks: Insmed (INSM), Illumina (ILMN)

TIPRANKS
·
Jul 17

Analysts Offer Insights on Healthcare Companies: Insmed (INSM), AbCellera Biologics (ABCL) and DBV Technologies SA – American (DBVT)

TIPRANKS
·
Jul 17

Insmed Announces Positive 12-Month TPIP PAH Data

TIPRANKS
·
Jul 17

Matt Phipps Reiterates Buy on Insmed, Citing Strong TPIP PAH Data, Solid Brinsupri/Arikayce Growth, and Overdone Share Pullback

TIPRANKS
·
Jul 17

Insmed Says Treprostinil Shows Sustained Benefit to Pulmonary Arterial Hypertension Patients

MT Newswires Live
·
Jul 16

Insmed’s inhalation powder shows efficacy and safety in arterial hypertension

TIPRANKS
·
Jul 16

Insmed Reports Positive 12-month TPIP Extension Data in Pulmonary Arterial Hypertension Study

Reuters
·
Jul 16

Insmed - Tpip Safe and Well-tolerated with no New Safety Signals Through Month 12

THOMSON REUTERS
·
Jul 16

Insmed Announces Positive 12-month Data from the Ongoing Open-label Extension Study of Treprostinil Palmitil Inhalation Powder (tpip) in Patients with Pulmonary Arterial Hypertension

THOMSON REUTERS
·
Jul 16

Insmed - Placebo Crossed Group on Tpip Achieves Similar Outcomes to Tpip Continued Group at 12 Months

THOMSON REUTERS
·
Jul 16

Insmed - Tpip Demonstrates Sustained Improvement and Reduced Mortality Risk at 12 Months

THOMSON REUTERS
·
Jul 16

Insmed is Maintained at Overweight by Wells Fargo

Dow Jones
·
Jul 15

Barclays Remains a Buy on Insmed (INSM)

TIPRANKS
·
Jul 13

Insmed Chair, CEO William Lewis Sells 10,699 Shares for $1.26 Million

Reuters
·
Jul 11

Insmed Price Target Maintained with a $207.00/share by Guggenheim

Dow Jones
·
Jul 10